|
English
|
正體中文
|
简体中文
|
2828323
|
|
???header.visitor??? :
32257436
???header.onlineuser??? :
954
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"xu jianming"???jsp.browse.items-by-author.description???
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立臺灣大學 |
2012 |
Brivanib (BRI) versus Sorafenib (SOR) as First-line Therapy in Patients with Unresectable, Advanced Hepatocellular Carcinoma (HCC): Results from the Phase 3 BRISK-FL Study
|
Johnson, Phillip; Qin, Shukui; Park, Joong-Won; Poon, Ronnie T.; Raoul, Jean-Luc; Philip, Philip A.; Hsu, Chih-Hung; Hu, Tsung-Hui; Heo, Jeong; Xu, Jianming; Lu, Ligong; Chao, Yee; Boucher, Eveline; Han, Kwang-Hyub; Paik, Seung Woon; Robles-Avina, Jorge; Kudo, Masatoshi; Liu, David; Ezzeddine, Rana; Walters, Ian; Cheng, Ann-Lii; 鄭安理; 徐志宏 |
| 國立臺灣大學 |
2005 |
Nuclear Hormone Receptor Coregulator Grip1 Suppresses While Src1a and P/ Cip Coactivate by Domain Specific Binding of Myod
|
張鑫; 張明富; YASUO HAMAMORI; XU JIANMING; CHANG, SHIN-C.; TERRY SALUNA; CHANG, MING- FU; BERT W O’MALLEY; LARRY KEDES |
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
